MPA
BMRN icon

Marvin & Palmer Associates’s BioMarin Pharmaceuticals BMRN Stock Holding History

Marvin & Palmer Associates’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-15,500
Closed -$1.12M – 65
2013
Q3 		$1.12M Buy
+15,500
New +$1.03M 0.73% 57

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Marvin & Palmer Associates's BMRN Position: Q4 2013 in Review

Marvin & Palmer Associates sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2013, closing a stake of 15,500 shares — an estimated $1.12M sold.

Marvin & Palmer Associates first reported a position in BMRN in Q3 2013 and held it in 1 quarter. The position peaked at $1.12M in Q3 2013. 307 funds tracked by Wall St. Rank hold BMRN as of Q4 2013.

  • Marvin & Palmer Associates reported no remaining BioMarin Pharmaceuticals position as of Q4 2013 after selling out during the quarter.
  • Marvin & Palmer Associates sold 15,500 BioMarin Pharmaceuticals shares in Q4 2013, an estimated $1.12M.
  • Marvin & Palmer Associates first reported a position in BioMarin Pharmaceuticals in Q3 2013 and held it in 1 quarter.
  • Marvin & Palmer Associates's BioMarin Pharmaceuticals position peaked at $1.12M in Q3 2013.
  • 307 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2013.

Based on Marvin & Palmer Associates's 13F filing for Q4 2013, filed 14 Feb 2014.